Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed to evaluate the efficacy, safety and tolerability of oxcarbazepine monotherapy in adults with partial seizures.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Carbamazepine; Oxcarbazepine

Criteria

Inclusion Criteria:

• males and females, 18 - 70 years of age;

• diagnosis of epilepsy, partial seizures;

• ineffective or intolerable present therapy with 1 antiepileptic drug, or none of previous therapy with antiepileptic drugs

Exclusion Criteria:

• progressive lesion of brain revealed by CT/MRI that performed no earlier than 2 years prior to screening;

• non-epileptic seizures;

• drug or alcohol dependence during a year prior to screening;

Other protocol-defined inclusion/exclusion criteria may apply.